Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 3/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.45 |
| ▸ | GCGR | P47871 | 1/20 | 0.45 |
| ▸ | GIPR | P48546 | 1/20 | 0.45 |
| ▸ | TFPI | P10646 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.44 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.42 |
| ▸ | CALCR | P30988 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507939 | 1.00 | GLP1R (0.46) | GLP1RECE1MUS81OPRL1GCGR | |
| SCHEMBL16507786 | 1.00 | GLP1R (0.46) | GLP1RECE1MUS81OPRL1GCGR | |
| SCHEMBL16508098 | 0.95 | OPRL1 (0.47) | GLP1RECE1MUS81OPRL1GCGR | |
| SCHEMBL16507777 | 0.94 | OPRL1 (0.46) | GLP1RECE1MUS81OPRL1GCGR | |
| SCHEMBL16507754 | 0.94 | OPRL1 (0.46) | GLP1RECE1MUS81OPRL1GCGR | |
| SCHEMBL16507940 | 0.94 | GLP1R (0.46) | GLP1RECE1MUS81OPRL1GCGR | |
| SCHEMBL16507907 | 0.94 | OPRL1 (0.47) | GLP1RECE1MUS81OPRL1GCGR | |
| SCHEMBL16508063 | 0.93 | OPRL1 (0.46) | GLP1RECE1MUS81OPRL1GCGR | |
| SCHEMBL16508057 | 0.93 | OPRL1 (0.46) | GLP1RECE1MUS81OPRL1GCGR | |
| SCHEMBL16507975 | 0.91 | NPY4R (0.43) | GLP1RECE1MUS81GCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | GLP1R 120/4885ECE1 2804/4885MUS81 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.